SCHEMBL680274

SCHEMBL680274

CCCCCCCCCCCCCCCCCCO[Si](OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.46
TSHR P16473 4/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SOAT1 P35610 1/20 0.42
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41
CYP3A4 P08684 3/20 0.41
MAPK1 P28482 2/20 0.41
TP53 P04637 2/20 0.41
NR1I2 O75469 2/20 0.40
CHRM2 P08172 2/20 0.40
ADRA2A P08913 2/20 0.40
OPRK1 P41145 2/20 0.40
HTR2B P41595 2/20 0.40
SLC6A3 Q01959 2/20 0.40
MLNR O43193 1/20 0.40
ESR1 P03372 1/20 0.40
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633823 1.00 LTA4H (0.46) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL11445945 1.00 LTA4H (0.46) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL4804045 0.98 LTA4H (0.47) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL28592042 0.95 SOAT1 (0.42) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL17391469 0.95 SOAT1 (0.42) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL17391462 0.95 SOAT1 (0.42) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL35139 0.95 SOAT1 (0.42) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL27943310 0.93 LTA4H (0.43) LTA4HTSHRLMNAALDH1A1SOAT1
SCHEMBL431649 0.92 LTA4H (0.47) LTA4HTSHRALDH1A1CYP3A4MAPK1
SCHEMBL19809255 0.92 LMNA (0.42) LTA4HTSHRLMNAALDH1A1SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098224-A1 PARAFFIN SUPPRESSANT COMPOSITIONS AND METHODS CHAMPIONX LLC (US) 2026-04-09 US disclosed
EP-2349956-B1 FARNESENE DIMERS AND/OR FARNESANE DIMERS AND COMPOSITIONS THEREOF AMYRIS INC (US) 2016-09-14 EP disclosed
US-8669403-B2 Farnesene dimers and/or farnesane dimers and compositions thereof EUAGORE, LLC 2014-03-11 US disclosed
US-20110282113-A1 FARNESENE DIMERS AND/OR FARNESANE DIMERS AND COMPOSITIONS THEREOF EUAGORE, LLC 2011-11-17 US disclosed
EP-2349956-A2 FARNESENE DIMERS AND/OR FARNESANE DIMERS AND COMPOSITIONS THEREOF Amyris, Inc. (US) 2011-08-03 EP disclosed
EP-0848053-B1 Mixtures of esterified carboxy-containing interpolymers and lubricants containing them LUBRIZOL CORP (US) 2010-09-29 EP disclosed
WO-2010042208-A2 FARNESENE DIMERS AND/OR FARNESANE DIMERS AND COMPOSITIONS THEREOF AMYRIS BIOTECHNOLOGIES, INC. (US) 2010-04-15 WO disclosed
US-7691792-B1 Lubricant compositions AMYRIS BIOTECHNOLOGIES, INC. (US) 2010-04-06 US disclosed
EP-1200541-B1 NITROGEN-CONTAINING ESTERIFIED CARBOXY-CONTAINING INTERPOLYMERS HAVING ENHANCED OXIDATIVE STABILITY AND LUBRICANTS CONTAINING THEM LUBRIZOL CORP (US) 2010-02-10 EP disclosed
US-7592295-B1 Farnesene dimers and/or farnesane dimers and compositions thereof AMYRIS BIOTECHNOLOGIES, INC. (US) 2009-09-22 US disclosed
US-6258761-B1 AN ESTERIFIED CARBOXY CONTAINING INTERPOLYMER BEING DERIVED FROM VINYL AROMATIC MONOMERS AND OTHER MONOMER BEING ATLEAST ONE ALPHA-BETA UNSATURATED ACYLATING AGENT, WITH A HYDROCARBYL SUBSTITUED CARBOXYLIC ACID AND A POLYAMINE THE LUBRIZOL CORPORATION 2001-07-10 US disclosed
WO-2001004242-A1 NITROGEN-CONTAINING ESTERIFIED CARBOXY-CONTAINING INTERPOLYMERS HAVING ENHANCED OXIDATIVE STABILITY AND LUBRICANTS CONTAINING THEM THE LUBRIZOL CORPORATION (US) 2001-01-18 WO disclosed
WO-2000077131-A1 LUBRICATING OIL ADDITIVES THE LUBRIZOL CORPORATION (US) 2000-12-21 WO disclosed
WO-2000077132-A1 LUBRICATING OIL ADDITIVES THE LUBRIZOL CORPORATION (US) 2000-12-21 WO disclosed
US-6071862-A COMPRISING FROM ABOUT 20% TO ABOUT 80% BY WEIGHT OF A DILUENT PREPARED BY REACTING A MIXTURE COMPRISING AN ESTERIFIED CARBOXY-CONTAINING INTERPOLYMER, A HYDROCARBYL SUBSTITUTED CARBOXYLIC ACID OR DERIVATIVE THEREOF, AN AMINE THE LUBRIZOL CORPORATION (US) 2000-06-06 US disclosed
US-5880074-A ADDITIVE CONCENTRATE COMPRISING DILUENT SELECTED FROM SYNTHETIC OIL OR NAPHTHENIC OILS, AN ESTER DERIVED FROM A CARBOXY-CONTAINING INTERPOLYMER HAVING REDUCED SPECIFIC VISCOSITY; GOOD LOW TEMPERATURE CHARACTERISTICS LUBRIZOL CORPORATION THE 1999-03-09 US disclosed
EP-0853115-A1 Additive concentrates containing mixtures of organic diluents and esterified carboxy-containing interpolymers and lubricants containing them The Lubrizol Corporation (US) 1998-07-15 EP disclosed
EP-0848053-A1 Mixtures of esterified carboxy-containing interpolymers and lubricants containing them The Lubrizol Corporation (US) 1998-06-17 EP disclosed
US-5707943-A EXTREME TEMPERATURE ADDITIVES, POUR POINT DEPRESSANTS, AMIDATION, ESTERIFICATION, TRANSESTERIFICATION, TRANSAMIDATION OF ACRYLIC ACID OR ANHYDRIDE COPOLYMERS THE LUBRIZOL CORPORATION (US) 1998-01-13 US disclosed
US-4604221-A Nitrogen-containing esters and lubricants containing them THE LUBRIZOL CORPORATION (US) 1986-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098224-A1 PARAFFIN SUPPRESSANT COMPOSITIONS AND METHODS PROX1, C5, C9 LTA4H 2103/4885TSHR 2817/4885LMNA 145/4885
US-20110282113-A1 FARNESENE DIMERS AND/OR FARNESANE DIMERS AND COMPOSITIONS THEREOF FNTB, FNTA, FDPS LTA4H 792/4885TSHR 4021/4885LMNA 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.